e not being disclosed. "We are deeply committed to our relationship with Novartis and pleased with the continued growth of our collaboration," said Michael J. Pellini, M.D., president and CEO, Foundation Medicine. "In addition to providing comprehensive genomic profiling for patients in Novartis clinical trials, t